Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selegiline in narcolepsy.

S E Roselaar1, N Langdon, C B Lock

  • 1University Department of Neurology, King's College School of Medicine, London, England.

Sleep
|October 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring recent patterns of migration of doctors to the United Kingdom: a mixed-methods study.

BMC health services research·2023
Same author

Drivers and barriers of international migration of doctors to and from the United Kingdom: a scoping review.

Human resources for health·2023
Same author

A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy.

Multiple sclerosis and related disorders·2021
Same author

A late haemorrhagic complication in an arteriovenous malformation cured with radiosurgery. Case report.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2012
Same author

The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

British journal of clinical pharmacology·2012
Same author

Bromocriptine and dopamine receptor stimulation.

British journal of clinical pharmacology·2012
Same journal

Nighttime light exposure is associated with metabolic dysfunction in schizophrenia: A cross-sectional analysis of the LENS study.

Sleep·2026
Same journal

Sleep Need Outcompetes Preparation: Reframing Sleep Initiation Through Naturalistic Behaviour.

Sleep·2026
Same journal

The Quest for Automated Pediatric Sleep Scoring: Are We There Yet?

Sleep·2026
Same journal

Sex Differences in the Sleep Architecture and Sleep-Disordered Breathing in C57BL/6 J Mice.

Sleep·2026
Same journal

Differential Effects of Prenatal Depression and Anxiety on Infant Sleep: Dual-Pathway Mechanisms Involving the HPA Axis and the Gut-Brain Axis.

Sleep·2026
Same journal

Metabolic Syndrome and Obstructive Sleep Apnea: Two Sides of the Same Coin.

Sleep·2026
See all related articles

Selegiline, a monoamine oxidase-B (MAO-B) inhibitor, showed effects on narcolepsy symptoms similar to dexamphetamine. Further evaluation is needed for this potential narcolepsy treatment.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Sleep Medicine

Background:

  • Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles.
  • Current treatments for narcolepsy often involve central stimulant drugs, which can have significant side effects.
  • Selegiline, a selective monoamine oxidase-B (MAO-B) inhibitor, is metabolized into amphetamine, suggesting potential therapeutic applications in narcolepsy.

Purpose of the Study:

  • To investigate the efficacy and safety of selegiline in treating narcolepsy.
  • To compare the effects of selegiline with no treatment and conventional central stimulant drugs.
  • To assess the impact of selegiline on narcolepsy severity, accessory symptoms, and mood.

Main Methods:

  • A 4-week study involving 21 subjects diagnosed with narcoleptic syndrome.

Related Experiment Videos

  • Participants were divided into groups receiving selegiline (20-30 mg daily), no treatment, or conventional stimulants (dexamphetamine or mazindol).
  • Measurements included narcolepsy symptom severity, accessory symptoms, mood, and urinary excretion of amphetamine and methamphetamine.

    • Main Results:

    • Selegiline demonstrated effects on alertness and mood comparable to dexamphetamine.
    • Sympathomimetic side effects were observed with selegiline, similar to those of dexamphetamine.
    • Urinary amphetamine excretion was significant in subjects taking selegiline, indicating its metabolic conversion.

    Conclusions:

    • Selegiline, at doses of 20-30 mg daily, shows potential as a treatment for narcolepsy.
    • The drug's effects are similar to dexamphetamine, with comparable side effects.
    • Further clinical trials are warranted to fully evaluate selegiline's therapeutic role in narcolepsy.